Detailed Narrative
Q4 FY25 Performance and Full Year Overview
Orchid Pharma reported Q4 FY25 sales of Rs. 237 crores, a 9% increase year-over-year, with an EBITDA of Rs. 40 crores. For the full fiscal year 2025, sales grew 13% to Rs. 922 crores, up from Rs. 819 crores in FY24, and EBITDA reached Rs. 156 crores, compared to Rs. 140 crores in the previous year. The company also achieved an 18-20% volume growth for FY25, despite absorbing a Rs. 6 crore one-time📎 expense for GMP inspections in Q3.
Antimicrobial Solutions (AMS) Division Update
The AMS division, launched last year to cater to hospital sales, closed FY25 with a team of 70 members and engagements with over 500 physicians. However, it incurred an EBITDA negative drag of Rs. 9 crores for the year. Management anticipates the division will remain a drag for roughly two more years before achieving profitability, as it is still in its build-out phase and developing its sales and marketing model.
Key Project Timelines and Challenges
The 7-ACA project faces a 6-month delay, with mechanical completion now targeted for December 2026 and the first commercial product for March 2027. For Enmetazobactam, while India shows strong traction with 10,000 patients treated in half a year (matching the full-year estimate), US commercialization is clouded by Allecra's insolvency filing. The Cefiderocol project remains on schedule, with first validation batches expected in Q4 2026 and commercial launch in Q2 2027, pending regulatory approval in India.
Dhanuka Laboratories Merger and Combined Entity Outlook
The National Capital Law Tribunal (NCLT) has cleared the merger of Dhanuka Laboratories into Orchid Pharma, with the legal process expected to conclude within FY26. The combined entity is projected to generate revenue in excess of Rs. 1,500 crore and an EBITDA of roughly Rs. 175 crore for FY26. Dhanuka Laboratories contributed Rs. 506 crores in sales and Rs. 48 crores in EBITDA for FY25, providing a stronger platform for future growth.
FY26 Outlook and Strategic Focus
Orchid Pharma anticipates a muted FY26 due to continued pricing pressure and the ramp-up of CAPEX for the 7-ACA facility. Despite this, the company's mid-teen margin aspiration remains intact, supported by volume growth, mixed optimization, and disciplined cost control. The company also plans to file 2 to 3 differentiated cephalosporin ANDAs for the US market within the next 12 to 18 months, aiming to stay at the forefront of complex anti-infectives.
Raw Material Pricing and Inventory Management
The company experienced a sudden surge in receivables and inventories in Q4 FY25, tying up cash, primarily due to sales in the last two months and higher inventory built in anticipation of higher sales amidst pricing pressure. Management noted a reduction in Pen-G prices, impacting products like Cefepime, and is monitoring the market for stabilization. They aim to liquidate excess inventory over the next few months.
US Market Strategy and API Supply
Historically, Orchid Pharma was dependent on a few customers for US market entry for its raw materials. To mitigate this, the company is now developing its own ANDAs and exploring partnerships with CMOs for US FDA-approved sites. While direct API supply to the US market is not anticipated in the next two years, development work is ongoing, and two customers are currently registering Orchid's API products.